
News|Videos|December 7, 2020
Patient Response to Treatment With FTX-6058
Pharmacy Times® interviewed Christopher Moxham of Fulcrum Therapeutics, on the results observed in his research when treating donors who were healthy or had sickle cell disease with FTX-6058.
Advertisement
Pharmacy Times® interviewed Christopher Moxham, the senior vice president of discovery research at Fulcrum Therapeutics, on his presentation at the 62nd ASH Annual Meeting and Exposition. The presentation discusses research into the induction of fetal hemoglobin by FTX6058, a novel small molecule development candidate.
In this video, Moxham explains the results observed in his research when treating donors who were healthy or had sickle cell disease with FTX-6058.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
mRNA COVID-19 Booster Outperforms Protein-Based Shot on Antibodies, But Both Cut Infections Over 12 Months
2
Navigating REMS: Challenges, Perspectives, and the Path Forward for Bispecific Antibody Programs
3
FDA Approves Zidesamtinib for Previously Treated ROS1-Positive NSCLC
4
Building a Pharmacist-Led Furoscix Workflow From Scratch
5


































































































